SCHEMBL20052954

SCHEMBL20052954

O[C@@]1(c2ccccc2)CO1

nearest known ligand 0.50

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 1/20 0.50
CHRNB2 P17787 2/20 0.44
SLC6A2 P23975 2/20 0.44
CHRNB4 P30926 2/20 0.44
CHRNA3 P32297 2/20 0.44
CHRNA4 P43681 2/20 0.44
SLC6A3 Q01959 1/20 0.44
HDAC1 Q13547 1/20 0.44
HDAC2 Q92769 1/20 0.44
OPRM1 P35372 3/20 0.38
OPRL1 P41146 3/20 0.38
OPRK1 P41145 2/20 0.38
AKR1C1 Q04828 1/20 0.37
ALOX15 P16050 1/20 0.37
CHRNA1 P02708 1/20 0.36
CHRNG P07510 1/20 0.36
CHRNB1 P11230 1/20 0.36
CHRND Q07001 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23326053 1.00 CYP1A2 (0.50) CYP1A2CHRNB2SLC6A2CHRNB4CHRNA3
SCHEMBL16743052 0.97 CYP1A2 (0.48) CYP1A2CHRNB2SLC6A2CHRNB4CHRNA3
SCHEMBL17627806 0.80 CYP1A2 (0.52) CYP1A2CHRNB2SLC6A2CHRNB4CHRNA3
SCHEMBL12235279 0.80 CHRNB2 (0.38) CYP1A2CHRNB2SLC6A2CHRNB4CHRNA3
SCHEMBL7262639 0.80 CYP1A2 (0.43) CYP1A2CHRNB2SLC6A2CHRNB4CHRNA3
SCHEMBL27536031 0.78 CYP1A2 (0.42) CYP1A2CHRNB2SLC6A2CHRNB4CHRNA3
SCHEMBL12656299 0.75 ALDH1A1 (0.41) CYP1A2OPRK1ALOX15
SCHEMBL29941731 0.75 CYP1A2 (0.51) CYP1A2HDAC1HDAC2OPRM1OPRL1
SCHEMBL109994 0.73 CYP1A2 (0.50) CYP1A2AKR1C1
SCHEMBL1322736 0.72 CHRM2 (0.46) CHRNB2SLC6A2CHRNB4CHRNA3CHRNA4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200102323-A1 ACC INHIBITORS AND USES THEREOF SCHRÖDINGER, INC. 2020-04-02 US disclosed
US-10472374-B2 ACC inhibitors and uses thereof GILEAD APOLLO, LLC (US) 2019-11-12 US disclosed
US-20190016732-A1 ACC INHIBITORS AND USES THEREOF Nimbus Apollo, Inc. 2019-01-17 US disclosed
US-9944655-B2 ACC inhibitors and uses thereof GILEAD APOLLO, LLC (US) 2018-04-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200102323-A1 ACC INHIBITORS AND USES THEREOF ACACA, ACACB, ACAT2 CYP1A2 1009/4885CHRNB2 3895/4885SLC6A2 3767/4885
US-10472374-B2 ACC inhibitors and uses thereof ACACA, ACACB, ACAT2 CYP1A2 1009/4885CHRNB2 3895/4885SLC6A2 3767/4885
US-20190016732-A1 ACC INHIBITORS AND USES THEREOF ACACA, ACACB, ACAT2 CYP1A2 1009/4885CHRNB2 3895/4885SLC6A2 3767/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.